

REED BUSINESS LAW – The World in Brief

ADMINISTRATION - New York State Executive Order 202.6, "Essential Businesses;"

New York State implemented Executive Order 202.6, defining “Essential Business;” also, implemented Executive Order 202.8, ordering non-essential businesses to reduce their workforce by 100% as of March 22, 2020, 8:00 pm. The entities included in EO 202.6 as examples of Essential Business is extensive, but they are by no means exhaustive. It is critical that businesses wishing to operate in New York State after March 22, 2020 assure their status under EO 202.6 and 202. 8. Reed Business Law provides legal consulting to clients who are unsure whether their businesses is essential or non-essential.

3 월 22 일, 오후 8 시를 기해서, 뉴욕주는 행정명령 제 202.6 과 제 202. 8 에 의거해, Essential Business 와 Non-Essential Business 를 정의하여 Non-essential business 의 근로자들을 100% 감축하라는 명령을 내렸습니다. 많은 기업들과 근로자들이 Essential Business 의 정의에 혼란을 겪고있는 바, 저희 로펌은 클라이언트들에게 행정명령 202.6 과 202.8 에 관하여 무료로 상담을 해드리고 있습니다.

Related news: <https://www.governor.ny.gov/news/governor-cuomo-issues-guidance-essential-services-under-new-york-state-pause-executive-order>

BIO-PHARMA – Coronavirus Test Kit from South Korea

Because of U.S. President Donald Trump’s request for coping with coronavirus pandemic, South Korean officials stated that South Korea was going to provide coronavirus test kits to US. South Korean official revealed that South Korea tested over 20,000 cases per day, and stored enough kits to send over to US. The FDA announced that it had granted Emergency Use Authorizations to Hologic for its Panther Fusion SARS-COV-2 Assay, and to Laboratory Corporation of America (LabCorp) for its COVID-19 RT-PCR test on Mar. 16, 2020, three days after President Trump declared a national public health emergency.

도널드 트럼프 미국대통령의 요청으로 한국의 코로나바이러스진단키트가 미국에 수입될예정입니다. 한국의 고위관계자에 따르면, 한국은 현재 충분한 양의 진단키트를 보유하고 있어서 조속히 미국수출가능한 상황입니다. 트럼프 대통령이 국가보건비상사태를 선포한 지 3 일후에, 미 FDA 는 코로나바이러스의 신속한 테스트를 위해 Laboratory Corporation of America 에게 Panther Fusion SARS-COV-2 Assay 의 긴급사용허가를 승인했습니다.

Related news: <https://www.bioworld.com/articles/433937-two-south-korean-covid-19-kits-look-overseas-look-fda-approval>

IMMIGRATION – Legal Immigrants in US Face Potential Risk for Status

Many of legal immigrants who have permission to reside or work in the United States potentially have immigration risk. Due to the closing of USCIS’s offices across the country, the foreign residents whose work permits are going to expire would deal with difficult situation. American Immigration Lawyers

‘Helping clients navigate a world filled with corporate, biopharma and immigration issues.’

David Reed, Partner +1.315.414.1338, dreed@reedbusinesslaw.com

Donghoo Sohn, Associate +1.315.882-7126, dsohn@reedbusinesslaw.com

Association (AILA) sent official letter to USCIS to demand the agency freeze all deadlines. USCIS stated that “agency is considering a number of options” on a case-by-case basis.

미국에서 근무하고 있는 외국인 근로자들은 코로나바이러스 팬데믹으로 인해 잠재적인 비자이슈를 겪게될수있습니다. USCIS의 미국내 모든 사무실의 현재 휴업상태이기때문에, 비자 만료가 다가오는 외국인 근로자들은 어려운 상황에 처하게 될수있습니다. 전미이민변호사협회는 해당 이슈에 대해, USCIS 에 성명을 제출하고 답변을 요구했습니다. USCIS 의 고위관계자는 여러가지 경우의 옵션을 고려중이라고 답변했습니다.

Related news: <https://thehill.com/homenews/administration/489569-legal-immigrants-at-risk-of-losing-status-during-coronavirus-pandemic>

US POLICIES - Can Companies be Forced to Produce in the US?

US based companies, in pharmaceutical, medical device and other industries, have spent the past decades taking advantage of lower taxes, lower labor rates, lower utility costs and lower environmental standards found in Asia and South America. This has arguably stretched supply chains, caused increased product recalls, increased corporate profits and had little impact on the prices being paid by American consumers for health care products. Tariff announcements by the US led to foreign companies seeking our help on creating operating units in the US. The global disruption caused by COVID-19 precautions have caused US companies to re-examine their multi-national manufacturing networks. Stayed tuned for more - - or call us today!

‘Helping clients navigate a world filled with corporate, biopharma and immigration issues.’

David Reed, Partner +1.315.414.1338, dreed@reedbusinesslaw.com

Donghoo Sohn, Associate +1.315.882-7126, dsohn@reedbusinesslaw.com